Cargando…

PD-L1 and c-MET expression and survival in patients with small cell lung cancer

BACKGROUND: Blocking the binding between the PD-1 and PD-L1 has been reported to produce antitumor responses. The MET/HGF axis appears to be another signaling pathway frequently altered in small cell lung cancer (SCLC). Our study was aimed to investigate the expression and prognostic roles of PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Lulu, Lu, Yunyun, Xu, Yanjun, Zhang, Gu, Huang, Zhiyu, Gong, Lei, Fan, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589556/ https://www.ncbi.nlm.nih.gov/pubmed/28903317 http://dx.doi.org/10.18632/oncotarget.9765

Ejemplares similares

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
por: Chen, Kaiyan, et al.
Publicado: (2020)

Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
por: Fan, Yun, et al.
Publicado: (2013)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
por: Xie, Mingying, et al.
Publicado: (2022)

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
por: Albitar, Maher, et al.
Publicado: (2018)

A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity
por: Xu, Yanjun, et al.
Publicado: (2017)

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
por: Xu, Yanjun, et al.
Publicado: (2020)

EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
por: Crees, Zachary D, et al.
Publicado: (2020)

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
por: Fischer, Alessa, et al.
Publicado: (2022)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
por: Song, Kyu Young, et al.
Publicado: (2020)

c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
por: Lux, Alexander, et al.
Publicado: (2019)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
por: Zhang, Qianning, et al.
Publicado: (2022)

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12
por: Xu, Yanjun, et al.
Publicado: (2023)

MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN
por: Gong, Jiaomei, et al.
Publicado: (2022)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases
por: Xu, Yanjun, et al.
Publicado: (2021)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

PD‐L1 positively regulates MET phosphorylation through inhibiting PTP1B
por: Lu, Shangyun, et al.
Publicado: (2021)

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver
por: Domènech, Marta, et al.
Publicado: (2021)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis
por: Peng, Zhiyu, et al.
Publicado: (2021)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
por: de Aguirre, Itziar, et al.
Publicado: (2006)

c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549
por: Min, Jingting, et al.
Publicado: (2022)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
por: Luo, Fan, et al.
Publicado: (2019)

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer
por: Zhou, Zi‐Chao, et al.
Publicado: (2022)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation
por: Ding, Nan, et al.
Publicado: (2020)

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
por: Li, Enliang, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sroilibs1a17822qdgl3r7cp1p